JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2005, 54(3):109-113

Pre-Formulation Studies of the H1-Antihistamine Loratadine for a Topical Dosage Form

Z. Capková, Z. Vitková, V. Vysokaiová
Farmaceutická fakulta Univerzity Komenského v Bratislave, Katedra galenickej farmácie

The paper focuses on the formulation of the antihistamine loratadine for hydrogels. In the first stage of this study, the evaluated polymer for the preparation of hydrogels was Carbopol® 980 of concentrations of 0.5, 0.8, and 1.0 %. The paper aimed to determine the optimal concentration of Carbopol® 980 in hydrogel formulation on the basis of the evaluation of the rheological properties and biological availability of loratadine from prepared hydrogels. The results of the study show 0.5% hydrogel of Carbopol® 980 to be optimal for loratadine from the standpoint of topical administration.

Keywords: hydrogels; Carbopol® 980; loratadine; liberation; rheological properties

Received: March 22, 2004; Accepted: May 26, 2004; Published: March 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Capková Z, Vitková Z, Vysokaiová V. Pre-Formulation Studies of the H1-Antihistamine Loratadine for a Topical Dosage Form. Čes. slov. farm. 2005;54(3):109-113.
Download citation

References

  1. Pátek, M.: Čas. čes. lekárníků, 1998; 6, 27.
  2. Gazdík, F, Janek, M.: Slov. Rev., 2000; 10, 68-70. Go to original source...
  3. Urbánek, R.: Remedia, 1993; 3, 216-221.
  4. Chalabala, M., Špringer, V., Čižmárik, J.: Pharma J., 1998; 8, 154-159.
  5. Gispert, J., Antonijoan, R., Barbanoj, M. et al.: Ann. Allerg. Asthma Imm., 2002; 89, 259-264. Go to original source... Go to PubMed...
  6. Ramboer, I., Bumtbacea, R., Lazarescu, D., Radu, R. R.: J. Int. Med. Res., 2000; 28, 69-77. Go to original source... Go to PubMed...
  7. Siergiejko, Z., Chyrek-Borowska, S.: Pol. Tyg. Lek., 1994; 49, 334-336.
  8. Monroe, E. W.: Clin. Ther., 1997; 19, 232-242. Go to original source... Go to PubMed...
  9. Československý liekopis, zväzok I. 4. vyd., Praha, Avicenum, 1987, s. 366-371.
  10. Haake, Betriebsanleitung Viscotester VT 500/VT 501, Germany, 1994, s. 24. Go to original source...
  11. El Ragehy, N. A., Badawey, A. M., El Khateeb, S. Z.: J. Pharm. Biomed. Anal., 2002; 28, 1041-1053. Go to original source... Go to PubMed...
  12. Indrayanto, G., Darmawan, L., Widjaja, S., Noorrizka, G.: J. Plan. Chrom. - Modern TLC, 1999; 12, 261-264.
  13. Slovenský liekopis, zväzok I. 1. vyd., Bratislava, Herba, 1997, s. 74.
  14. Keil, B. et al.: Laboratórní technika biochemie. Praha, ČSA, 1959, s. 303.
  15. Šubová, M., Vitková, Z., Bírová, M.: Zborník abstraktov, 32. konferencia Syntéza a analýza liečiv, Bratislava
  16. -19. 9., s. 91.




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.